ESMO 2023 – Lumakras still looks like a colorectal also-ran
And first data with a low dose are particularly unimpressive.
ESMO 2023 – Pluvicto’s big splash gets an early preview
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Triple meeting 2023 – a p53 double-whammy for PMV
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
